^GSPC - S&P 500
| Previous Close | 2,822.48 |
| Open | 2,810.79 |
| Volume | 1,996,583,605 |
| Day's Range | 2,821.99 - 2,835.41 |
| 52 Week Range | 2,346.58 - 2,940.91 |
| Avg. Volume | 3,906,882,166 |
Yahoo Finance•10 minutes agoS&P 500, Nasdaq close at highest levels in 5 months
U.S. stocks opened higher to kick off the week.
Yahoo Finance•4 hours agoThere is one missing factor in 2019’s epic stock market rebound
Corporate buybacks have been driving the stock market's 2019 rally.
- MarketWatch•11 minutes ago
Cannabis producer Tilray stock rises after losses widen, revenue tops estimates
Tilray Inc. shares gained more than 4% in the extended session Monday after the cannabis producer reported wider-than-expected losses but beat Wall Street revenue estimates. The company reported fourth-quarter net income of $31 million, or 33 cents a share, compared with losses of $2.9 million, or 4 cents a share, in the year-ago period. Revenue rose to $15.5 million from $5.1 million in the year-ago period. Analysts surveyed by FactSet had estimated losses of 14 cents a share on revenue of $14.1 million. For the first quarter, analysts expect losses of 19 cents a share on sales of $19 million. Tilray stock has fallen 53% in the past six months, with the S&P 500 index falling 2.8%.
Reuters•13 minutes agoWall Street ends higher, with biggest boost from banks
Banks helped lead Wall Street higher on Monday, while Boeing and Facebook were a drag and investors eyed this week's Federal Reserve meeting for affirmation of its commitment to "patient" monetary ...
- Bloomberg•17 minutes ago
U.S. Equities' Momentum Carries Into Fed Week: Markets Wrap
U.S. equity benchmarks rose at the start of a week filled with potentially significant catalysts -- from central bank meetings, geopolitical developments and economic data. Financials and consumer stocks also advanced, while the Dow Jones Industrial Average fought to stay positive even as Boeing declined on reports that the U.S. Transportation Department was examining the 737 Max’s design certification. Equities have been trending upward, and volatility declining, on expectations the Fed will point the way to just one rate hike in 2019 when it meets this week.
- Investor's Business Daily•5 minutes ago
HealthEquity Stock Falls Late After Guiding Earnings Low
Health savings account custodian HealthEquity reported strong Q4 earnings late Monday but the stock retreated from a buy point on weak forecasts.
- MarketWatch•20 minutes ago
Stocks finish slightly higher as Dow picks up fourth straight gain
Stocks closed on a positive note on Monday to extend last week's broad-based rally even as Boeing's travails dragged on the blue-chip Dow. The S&P 500 rose less than 0.4% to end near 2,833. The Dow Jones Industrial Average advanced 65 points, or less than 0.3%, to finish near 25,912, based on preliminary numbers. The Nasdaq Composite rose 0.3% to end around 7,714. The Dow notched its fourth straight consecutive gain. The S&P and Nasdaq hit a fresh 52-week high. Major stock-market benchmarks built on last week's rally that lifted the S&P 500 above its long-term resistance level at 2,800. Investors said they would mostly look ahead to the Fed's two-day meeting set to conclude on Wednesday, with expectations for the central bank to lower its forecasts for interest rates. In company news, shares of Boeing Co. were down 2% after The Wall Street Journal said that federal prosecutors and Department of Transportation officials were investigating the development of the firm's 737 Max jetliners.
- Barrons.com•35 minutes ago
Why the S&P 500 Rally Can Continue, According to Credit Suisse
Equity strategist Anthony Golub sees the index heading to 3025, based on expanding valuation multiples. Many fund managers haven’t re-risked their portfolios, he writes.
Associated Press•36 minutes agoEnergy companies lead US stock indexes slightly higher
U.S. stock indexes edged higher in afternoon trading Monday, riding the momentum from a solid rally last week.
- MarketWatch•1 hour ago
Why stocks can continue to rally in short term after investors suffered ‘parable of the boiling frog’
Complacent stock-market investors got burned last year, much like the proverbial frog in slowly boiling water, say Société Générale analysts. With the market on the rebound and the Fed on hold, investors might be able to safely slip back into the water, but they need to watch the temperature.
- MarketWatch•1 hour ago
Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment
Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed to meet its primary endpoint of improvement over placebo. The stock was the biggest decliner listed on major U.S. exchanges, with volume reaching 5.5 million shares, or about 22 times the full-day average. Meanwhile, the company said the trial of its lead candidate AKB-9778 was found did to be safe and well tolerated and showed some encouraging in some secondary endpoints. "While we are disappointed in the primary endpoint results of this study, we are nevertheless encouraged by the fact that several other promising findings observed in our prior 3-month Phase 2a trial have been prospectively confirmed in this 1-year trial," said Chief Executive Stephen Hoffman. The company said it plans to provide an update on the status of AKB-9778 after a full analysis. The stock has now lost 37% over the past 3 months while the iShares Nasdaq Biotechology ETF has gained 16% and the S&P 500 has tacked on 11%.
- Reuters•2 hours ago
Wall Street inches higher ahead of Fed policy meeting
Wall Street edged higher on Monday as declines in Boeing and Facebook held gains in check and investors eyed this week's Federal Reserve meeting for affirmation of the central bank's commitment to "patient" monetary policy. Coming on the heels of the S&P 500's best week since November, the benchmark index currently hovers about 3.4 percent below its all-time high reached in September. "People were so pessimistic around year-end, but the market has since had a tremendous rebound and now we're in a wait-and-see phase," said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia.
- MarketWatch•2 hours ago
Mylan voluntarily recalls two lots of its levoleucovorin injection
Mylan N.V. said on Monday that it is voluntarily recalling two lots of its levoleucovorin injection due to the discovery of foreign particulates in the drug. Levoleucovorin is used to reduce harmful effects of methotrexate, a medication used to treat patients with osteosarcoma. It is also used in combination chemotherapy with 5-fluorouracil to treat patients with advanced metastatic colorectal cancer. Mylan said it discovered the presence of copper salts in the levoleucovorin during 12-month stability testing. Such particulates can lead to severe health complications like vasculitis, allergic reactions and pulmonary embolism. The drug maker has not received any reports of adverse events related to the recall and said it notified its distributors and customers by letter. Shares of Mylan have fallen 2.2% in the year to date, while the S&P 500 has gained 11.1%.
- MarketWatch•2 hours ago
Stocks edge higher ahead of Fed meeting; Boeing drags on Dow
U.S. stocks trade modestly higher as investors look ahead to this week’s meeting of Federal Reserve policy makers; losses for aircraft maker Boeing threaten to again weigh on the Dow Jones Industrial Average.
- MarketWatch•3 hours ago
Microsoft's stock riding 7-day win streak toward another record close
Shares of Microsoft Corp. rose 0.8% in afternoon trade Monday, putting them on track for a 7th-straight gain toward a 2nd-straight record close. The win streak would be the longest since it rose for 8-straight sessions as of Aug. 9, 2018. The software and cloud-computing company continues to hold its lead as the largest U.S. company by market capitalization, ahead of second-place Apple Inc. , third-place Amazon.com Inc. and fourth-place Alphabet Inc. . Wall Street analysts are overwhelming bullish on Microsoft's stock, as 31 of 34 analysts surveyed by FactSet rate it the equivalent of buy, 2 rate it a hold and just one rates it the equivalent of sell. The average price target of $126.37 implies an 8.1% climb from current levels. Microsoft shares have soared 24% over the past 12 months, while Apple's stock has gained 5.5%, Amazon shares have tacked on 11% and Alphabet shares have edged up 4.6%. The Dow Jones Industrial Average has gained 3.7% the past year.
- MarketWatch•3 hours ago
Kevin Tsujihara is stepping down as chairman, CEO of Warner Bros. amid probe of behavior
WarnerMedia said Monday that Kevin Tsujihara is stepping down from his role as chairman and CEO of Warner Bros. Entertainment. WarnerMedia CEO John Stankey said it was in the best interests of the company and its employees and partners for the executive to leave. "Kevin acknowledges that his mistakes are inconsistent with the company's leadership expectations and could impact the company's ability to executive going forward," he said in a short statement. The company is continuing to work with a law firm to complete an investigation with Tsujihara's cooperation, said the statement. Tsujihara is alleged to have pushed for auditions for actress Charlotte Kirk with whom he was having a sexual relationship, according to media reports. Shares of AT&T, which owns WarnerMeda after it acquired Time Warner, shares were up slightly Monday, but have fallen 17% in the last 12 months, while the S&P 500 has gained 2.8%.
- MarketWatch•3 hours ago
Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study
Shares of Daré Bioscience Inc. rocketed 129% on very heavy volume toward a 13-month high in afternoon trade Monday, after the biopharmaceutical company announced positive findings for the use of its DARE-VVA1 product candidate in treating vulvar and vaginal atrophy (VVA). The stock was the biggest percentage gainer listed on major U.S. exchanges, even though it pared earlier gains of as much as 253%. Volume swelled to 37.8 million shares, compared with the full-day average of about 82,500 shares and enough to make the stock the most active on the Nasdaq exchange. The company said a self-administered vaginal suppository containing tamoxifen administered to four healthy postmenopausal women with VVA showed "significant improvements" in reducing vaginal pH and vaginal dryness, without significant absorption of tamoxifen. "If successful, DARE-VVA1 could be the first and only vaginally administered tamoxifen product approved by the FDA for the treatment of VVA in hormone-receptor positive breast cancer patients," the company said in a statement. The stock has now more than tripled year to date (up 218%), while the iShares Nasdaq Biotechnology ETF has climbed 18% and the S&P 500 has gained 13%.
- TheStreet.com•3 hours ago
6 Japanese Stocks Likely to Suffer Until August
For international investors looking for exposure to Japanese stocks, the JPX-Nikkei Index 400 is an extremely useful vehicle. The index of 400 stocks is designed with them in mind, screening for quality companies with international standards of corporate governance and attention to shareholder returns. Fortunately, the brokerage Nomura has screened Japanese stocks and is predicting which ones will be put into the index, and which will be taken out.
- CNBC•3 hours ago
The Fed may soon let inflation run a little hotter than usual, Goldman says
The Fed has begun a monthslong review of its policy framework to consider alternative approaches to targeting inflation, and Goldman Sachs believes the central bank will decide to allow overshoots of its inflation goal next year. "If implemented ... this change would decrease the likelihood of further near-term policy tightening and lead to a small and gradual increase in both expected and realized price inflation," says Goldman's equity strategist Ben Snider. Since 2012, the Fed has always been attempting to hit a 2 percent target, but inflation has fallen short through much of the recovery.
- Bloomberg•4 hours ago
Index Funds Sure Don’t Seem Like Libor
Berkeley law professor also implied that the indexes on which the funds are based could be subject to manipulation and other abuses. Technically speaking, index funds don't track a nebulous groups of stocks, but rather very specific indexes. For starters, index-based mutual funds and exchange-traded funds get assembled using a particular methodology that determines the specific holdings in that index.
GuruFocus.com•4 hours agoThe Berkshire Hathaway 2018 Shareholder Letter: A Changing of the Scorecard
My son, who is now 4 years old, claims that Warren Buffett (Trades, Portfolio) is his favorite super hero. Of course, this is because my son's other super hero, his father, tells him Buffett is so. My son regularly explains to me why Buffett is a super hero.
- Yahoo Finance Video•5 hours ago
The Dow Jones is ‘very close to a golden cross’
Sam Stovall, CFRA Research Equity Strategist, says the Dow Jones is “very close to a golden cross”, which is when the 50-day moving average breaks above the 200-day moving average, and that “could be a positive sentiment indicator in the near term.” Yahoo Finance’s Alexis Christoforous speaks to Scott Gamm, Brian Sozzi and Stovall.
